Tazarotene

Tazarotene
Clinical data
Trade names	Tazorac, others
AHFS/Drugs.com	Monograph
Routes of; administration	Topical
ATC code	D05AX05 (WHO) ; D05AX55 (WHO) (combination with ulobetasol);
Legal status
Legal status	CA: ℞-only / Schedule D; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	>99%
Elimination half-life	19 Hours
Identifiers
	IUPAC name ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate;
CAS Number	118292-40-3 ;
PubChem CID	5381;
IUPHAR/BPS	6952;
DrugBank	DB00799 ;
ChemSpider	5188 ;
UNII	81BDR9Y8PS;
KEGG	D01132 ;
ChEBI	CHEBI:32184 ;
ChEMBL	ChEMBL1657 ;
CompTox Dashboard (EPA)	DTXSID5046691 ;
ECHA InfoCard	100.115.380
Chemical and physical data
Formula	C21H21NO2S
Molar mass	351.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)c1ccc(nc1)C#Cc3ccc2SCCC(c2c3)(C)C;
	InChI InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3 ; Key:OGQICQVSFDPSEI-UHFFFAOYSA-N ;
	(verify)

Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids.

Tazarotene was approved for medical use in 1997 and is available as a generic medication.